Longitudinal Urban Cohort Ageing Study

https://neurodegenerationresearch.eu/survey/longitudinal-urban-cohort-ageing-study/

Title of the cohort

Longitudinal Urban Cohort Ageing Study

Acronym for cohort

LUCAS

Name of Principal Investigator

Title	Dr.
First name	Ulrike
Last name	Dapp

Address of institution where award is held

Institution	ertinen-Haus, Centre for Geriatrics and Gerontology, Research Department
Street Address	Sellhopsweg 18-22
City	Hamburg
Postcode	22459

Country

Germany

Website

www.geriatrie-forschung.de

Contact email

forschung@albertinen.de

Funding source

1. The cohort includes, or expects to include, incidence of the following conditions

1. The cohort includes, or expects to include, incidence of the following conditions

- Alzheimer’s disease and other dementias
- Neurodegenerative disease in general

When studies on the above condition(s) are expected to become possible

Already possible

2a. Stated aim of the cohort

To enlighten the black box of the ageing process by establishing a longitudinal cohort making use of a

randomised controlled trial (RCT) carried out in 2000 with over 3,300 independent senior citizens in the community of Hamburg. Information about pre-clinical markers for healthy ageing vs. the development of functional decline, has been collected multidimensionally in an interdisciplinary process since 2000.

2b. Features distinguishing this cohort from other population cohorts
3a. i) Number of publications that involve use of cohort to date
0
3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)
3b. Publication list/link to where data or publications are accessible (if available)
3c. Information (i.e. research findings) expected to be gained from the population cohort
4a. Study criteria: age range of participants at recruitment

Age in years from:	60
To (‘until death’ if applicable):	98

4b. Study criteria: inclusion criteria

patients 60 + years in participating general practices (GP) in Hamburg in year 2000

4c. Study criteria: exclusion criteria

patients needing help in basic activities of daily life; patients obtaining nursing care according to the German long-term care insurance (Pflegeversicherung I-III); patients with cognitive impairment; patients with terminal disease and/or patients unable to understand German

5. Size of the cohort (i.e. number of participants enrolled)

1,000 – 5,000 participants

6a. Measures used to characterise participants

multidimensional dataset using self-administered questionnaires in waves with whole cohort plus multidimensional assessments with randomly selected subgroups

6b. Additional measures for participants with a clinical disorder
6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)

functional status, nursing care (Pflegestufe), death

7. Study design

Longitudinal

8. Cases matched by

- Age
- Sex
- Physical ability

9a. Does the study include a specialised subset of control participants

Yes

9b. If yes, description of specialised subset of control participants
10a. i) Data collection start date

01-12-2000

10a. ii) Data collection end date
10a iii) Data collection for this study is

- Data collection ongoing
- Data analysis ongoing

10b. Plans to continue the cohort study beyond the current projected end date

- Yes – intend to apply for funding

11. Data collected
12. System in place to enable re-contact with patients for future studies
13a. Format and availability of data stored in a database
Language used:
13b. Format and availability of data held as individual records
Language used:
14a. Are data available to other groups

Yes

14b. Access policy/mechanisms for access if data are available to other groups

- Other criteria (please specify)
- only for LUCAS consortium partners until end of funding

15. Data sharing policy specified as a condition of use

Data made publicly available after a specified time point

16a. Are tissues/samples/DNA available to other groups

No

16b. i) Description of available tissues/samples/DNA
16b. ii) Form available tissues/samples/DNA are supplied in
16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data
17. Is information on biological characteristics available to other groups

- No